Mohs et al. demonstrated that the activation of Nrf2 in patients with NASH correlates with the grade of inflammation, and in vivo data suggested that NRF2 activation in chronic liver disease is protective by alleviating fibrogenesis and progression of HCC [31]. The gene discussed is NFE2L2; the disease is metabolic dysfunction-associated steatohepatitis.